Display options
Cite
Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, et al. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract. 2011;2011:269515doi: 10.1155/2011/269515.
Yazdanpanah, M. J., Banihashemi, M., Pezeshkpoor, F., Khajedaluee, M., Famili, S., Tavakoli Rodi, I., & Yousefzadeh, H. (2011). Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatology research and practice, 2011269515. https://doi.org/10.1155/2011/269515
Yazdanpanah, Mohamad Javad, et al. "Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis." Dermatology research and practice vol. 2011 (2011): 269515. doi: https://doi.org/10.1155/2011/269515
Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, Yousefzadeh H. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract. 2011;2011:269515. doi: 10.1155/2011/269515. Epub 2011 Jul 06. PMID: 21747837; PMCID: PMC3130957.
Copy Download .nbib Format: NLM
Share it on

Dermatol Res Pract. 2011;2011:269515. doi: 10.1155/2011/269515. Epub 2011 Jul 06.

Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis.

Dermatology research and practice

Mohamad Javad Yazdanpanah, Mahnaz Banihashemi, Fakhrozaman Pezeshkpoor, Mohammad Khajedaluee, Sororozaman Famili, Iman Tavakoli Rodi, Hadis Yousefzadeh

Affiliations

  1. Research Center for Skin Disease and Cutaneous Leishmaniasis, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.

PMID: 21747837 PMCID: PMC3130957 DOI: 10.1155/2011/269515

Abstract

The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The first group was treated with oral zinc sulfate (10 mg/kg/day during 45 days period), and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). Acceptable cure after completing 45 days of followup occurred in 30.2% of lesions in first group, while this was 35.5% for the second group. There is not any significant difference between the two treatment groups (P = 0.42). Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without serious side effect.

References

  1. World Health Stat Q. 1992;45(2-3):267-75 - PubMed
  2. Dermatology. 2004;209(1):46-9 - PubMed
  3. Clin Infect Dis. 2001 Dec 1;33(11):1847-51 - PubMed
  4. Ann Trop Med Parasitol. 2005 Mar;99(2):131-9 - PubMed
  5. Ann Trop Med Parasitol. 2006 Jan;100(1):33-8 - PubMed
  6. Travel Med Infect Dis. 2007 May;5(3):150-8 - PubMed
  7. Clin Dermatol. 1999 May-Jun;17(3):249-54 - PubMed
  8. Clin Exp Dermatol. 1997 Jul;22(4):169-73 - PubMed
  9. Clin Exp Dermatol. 2001 Jan;26(1):21-6 - PubMed
  10. Mem Inst Oswaldo Cruz. 1998 Nov-Dec;93(6):831-7 - PubMed

Publication Types